| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $11.0M | -42.3% |
| R&D Expense | $26.9M | +52.1% |
| SG&A Expense | $18.2M | +52.3% |
| Operating Income | -$62.1M | -487.7% |
| Pre-tax Income | -$57.5M | -476.8% |
| Income Tax | $0 | -100.0% |
| Net Income | -$57.5M | -476.1% |
| EPS (Basic) | -$2.15 | -367.4% |
| EPS (Diluted) | -$2.15 |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $30.3M | -40.0% |
| Short-term Investments | $2K | -86.7% |
| Accounts Receivable | $3.6M | +284.8% |
| Current Assets | $36.6M | -32.1% |
| Total Assets | $36.9M | -31.7% |
| Current Liabilities | $11.3M | +179.4% |
| Total Liabilities | $11.3M | +179.4% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$25.6M | -2200.0% |
| Investing Cash Flow | $1.2M | — |
| Financing Cash Flow | $4.2M | -53.4% |
| -367.4% |
| Stockholders' Equity |
| $6.7M |
| -86.5% |